Hosted on MSN
Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results
Eli Lilly (LLY) reported better-than-expected earnings for the second quarter on Thursday. But disappointing results of its much-awaited oral GLP-1 pill sent the stock down 13% in early trading. The ...
Press Secretary Karoline Leavitt read President Trump’s letter to several pharmaceutical companies, which asked them to provide ‘American families immediate relief from the vastly inflated drug prices ...
AstraZeneca (AZN) and Eli Lilly (NYSE:LLY) have become the latest leading drugmakers to reconsider their investment options in the U.K. after Merck (MRK) canceled plans for a £1B research center in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback